These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

62 related articles for article (PubMed ID: 10544040)

  • 1. Structural dependence of the cellular isoform of prion protein on solvent: spectroscopic characterization of an intermediate conformation.
    Pergami P; Bramanti E; Ascoli GA
    Biochem Biophys Res Commun; 1999 Nov; 264(3):972-8. PubMed ID: 10544040
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Physical studies of conformational plasticity in a recombinant prion protein.
    Zhang H; Stockel J; Mehlhorn I; Groth D; Baldwin MA; Prusiner SB; James TL; Cohen FE
    Biochemistry; 1997 Mar; 36(12):3543-53. PubMed ID: 9132005
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular model of an alpha-helical prion protein dimer and its monomeric subunits as derived from chemical cross-linking and molecular modeling calculations.
    Kaimann T; Metzger S; Kuhlmann K; Brandt B; Birkmann E; Höltje HD; Riesner D
    J Mol Biol; 2008 Feb; 376(2):582-96. PubMed ID: 18158160
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Scrapie infectivity is independent of amyloid staining properties of the N-terminally truncated prion protein.
    Wille H; Prusiner SB; Cohen FE
    J Struct Biol; 2000 Jun; 130(2-3):323-38. PubMed ID: 10940236
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of the 132-160 region in prion protein conformational transitions.
    Torrent J; Alvarez-Martinez MT; Liautard JP; Balny C; Lange R
    Protein Sci; 2005 Apr; 14(4):956-67. PubMed ID: 15772306
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preventing misfolding of the prion protein by trimethylamine N-oxide.
    Bennion BJ; DeMarco ML; Daggett V
    Biochemistry; 2004 Oct; 43(41):12955-63. PubMed ID: 15476389
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Full-length prion protein aggregates to amyloid fibrils and spherical particles by distinct pathways.
    El Moustaine D; Perrier V; Smeller L; Lange R; Torrent J
    FEBS J; 2008 May; 275(9):2021-31. PubMed ID: 18355314
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of detergents on the secondary structures of prion protein peptides as studied by CD spectroscopy.
    Kuroda Y; Maeda Y; Sawa S; Shibata K; Miyamoto K; Nakagawa T
    J Pept Sci; 2003 Apr; 9(4):212-20. PubMed ID: 12725242
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-level expression and characterization of a purified 142-residue polypeptide of the prion protein.
    Mehlhorn I; Groth D; Stöckel J; Moffat B; Reilly D; Yansura D; Willett WS; Baldwin M; Fletterick R; Cohen FE; Vandlen R; Henner D; Prusiner SB
    Biochemistry; 1996 Apr; 35(17):5528-37. PubMed ID: 8611544
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Different structural stability and toxicity of PrP(ARR) and PrP(ARQ) sheep prion protein variants.
    Paludi D; Thellung S; Chiovitti K; Corsaro A; Villa V; Russo C; Ianieri A; Bertsch U; Kretzschmar HA; Aceto A; Florio T
    J Neurochem; 2007 Dec; 103(6):2291-300. PubMed ID: 17919292
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thermal stability and conformational transitions of scrapie amyloid (prion) protein correlate with infectivity.
    Safar J; Roller PP; Gajdusek DC; Gibbs CJ
    Protein Sci; 1993 Dec; 2(12):2206-16. PubMed ID: 7905316
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differences between the prion protein and its homolog Doppel: a partially structured state with implications for scrapie formation.
    Nicholson EM; Mo H; Prusiner SB; Cohen FE; Marqusee S
    J Mol Biol; 2002 Feb; 316(3):807-15. PubMed ID: 11866533
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Conformational polymorphism of the amyloidogenic peptide homologous to residues 113-127 of the prion protein.
    Satheeshkumar KS; Jayakumar R
    Biophys J; 2003 Jul; 85(1):473-83. PubMed ID: 12829502
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structural intermediates in the putative pathway from the cellular prion protein to the pathogenic form.
    Jansen K; Schäfer O; Birkmann E; Post K; Serban H; Prusiner SB; Riesner D
    Biol Chem; 2001 Apr; 382(4):683-91. PubMed ID: 11405232
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The key-role of tyrosine 155 in the mechanism of prion transconformation as highlighted by a study of sheep mutant peptides.
    Bertho G; Bouvier G; Hoa GH; Girault JP
    Peptides; 2008 Jul; 29(7):1073-84. PubMed ID: 18455265
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Binding of prion protein to lipid membranes and implications for prion conversion.
    Sanghera N; Pinheiro TJ
    J Mol Biol; 2002 Feb; 315(5):1241-56. PubMed ID: 11827491
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The prion protein: Structural features and related toxic peptides.
    Ronga L; Tizzano B; Palladino P; Ragone R; Urso E; Maffia M; Ruvo M; Benedetti E; Rossi F
    Chem Biol Drug Des; 2006 Sep; 68(3):139-47. PubMed ID: 17062011
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro conversion of full-length mammalian prion protein produces amyloid form with physical properties of PrP(Sc).
    Bocharova OV; Breydo L; Parfenov AS; Salnikov VV; Baskakov IV
    J Mol Biol; 2005 Feb; 346(2):645-59. PubMed ID: 15670611
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Prion protein structure and its relationships with pathogenesis].
    Muramoto T
    Rinsho Shinkeigaku; 2003 Nov; 43(11):813-6. PubMed ID: 15152472
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assembly of natural and recombinant prion protein into fibrils.
    Leffers KW; Wille H; Stöhr J; Junger E; Prusiner SB; Riesner D
    Biol Chem; 2005 Jun; 386(6):569-80. PubMed ID: 16006244
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.